Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors

Inclusion Criteria:

Histologically confirmed diagnosis of 1 of the following malignancies:

Leukemia

Lymphoid, myeloid, or mixed lineage

Relapsed (in second or greater relapse) or refractory disease, confirmed by 1 of the following:

Bone marrow relapse, defined as either M3 bone marrow (> 25% blasts in the bone marrow aspirate) OR M2 bone marrow (5-25% blasts in the bone marrow aspirate) at any time after complete remission is attained
CNS relapse, defined as at least 5 WBC/mL by cytospin of any cerebrospinal fluid (CSF) specimen OR less than 5 WBC/mL by cytospin of 2 consecutive CSF specimens obtained >= 4 weeks apart and having definitive confirmation that blasts are derived from the original leukemic clone by molecular cytogenetics, multiparameter flow cytometry, or immunostaining of >= 2 antigens
Patients with underlying chronic myeloid leukemia must have > 25% blasts in the bone marrow aspirate
Patients with M3 bone marrow AND extramedullary sites of disease, other than leptomeningeal disease, are eligible

Solid tumor

One of the following tumor types:

Neuroblastoma
Ewing's sarcoma
Osteosarcoma
Desmoplastic small round cell tumor
Rhabdomyosarcoma
Progressed after prior standard therapy OR no effective standard therapy exists
Measurable or nonmeasurable disease
No known brain metastases

No active leptomeningeal leukemia, defined by the following criteria:

WBC > 5/mm^3 in cerebrospinal fluid (CSF)
Unequivocal confirmation of leukemic blasts in CSF by cell morphology
No symptomatic CNS disease (e.g., cranial nerve abnormalities) without cytologic abnormality in CSF
Performance status - Karnofsky 70-100% (for patients > 10 years of age)
Performance status - Lansky 70-100% (for patients =< 10 years of age)
More than 8 weeks
Absolute neutrophil count >= 750/mm^3
Platelet count >= 75,000/mm^3 (transfusion independent)
Hemoglobin >= 8.5 g/dL (transfusion allowed)
Bilirubin < 1.5 mg/dL
ALT and AST =< 2.5 times upper limit of normal (ULN)
INR =< 1.5 times ULN
Albumin > 2.0 g/dL
Creatinine =< 1.5 times ULN for age
Creatinine clearance or radioisotope glomerular filtration rate > 60 mL/min
Ejection fraction >= 50%
Shortening fraction >= 28%

QTc < 450 msec for men (470 msec for women)

No congenital long QT syndrome
LVEF > 40% by MUGA
No symptomatic congestive heart failure
No cardiac arrhythmia
No New York Heart Association class III or IV heart failure
No myocardial infarction within the past year
No uncontrolled dysrhythmias
No poorly controlled angina
More than 12 months since active ischemic heart disease
No history of serious ventricular arrhythmia (ventricular tachycardia or ventricular fibrillation >= 3 beats in a row)
No left bundle branch block
No other significant cardiac disease
No pulmonary fibrosis by radiography
No ongoing or active bacterial or fungal infection
No other uncontrolled illness
No psychiatric illness or social situation that would preclude study compliance
No history of serious allergic reaction attributed to eggs or dimethyl sulfoxide
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception
Recovered from all immunotherapy
At least 6 months since prior allogeneic stem cell transplantation
At least 3 months since prior autologous stem cell transplantation
At least 2 weeks since prior biologic agents (e.g., monoclonal antibodies)
At least 1 week since prior filgrastim (G-CSF) or sargramostim (GM-CSF)
Recovered from all prior chemotherapy
At least 2 weeks since prior chemotherapy (for patients with leukemia only)
At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) (for patients with solid tumors)
No prior oxaliplatin
No concurrent corticosteroids except for the treatment of adrenal crises in patients with suppressed hypothalamic-pituitary-adrenal axis response OR for treatment of allergic reactions to medications or blood products
Recovered from all prior radiotherapy
At least 6 months since prior radiotherapy to >= 50% of the pelvis
At least 6 months since prior radiotherapy to substantial bone marrow, including total body irradiation
At least 4 weeks since prior local (small port) radiotherapy
No prior radiotherapy to the heart
At least 1 week since prior retinoids
No concurrent antiretroviral therapy for HIV-positive patients
No concurrent medication to control arrhythmias
No concurrent medications that prolong or may prolong QTc interval
No other concurrent investigational agents
No other concurrent anticancer therapy